Panel of serum biomarkers for differential diagnosis of idiopathic interstitial lung disease and interstitial lung disease-secondary to systemic autoimmune rheumatic disease
PLOS ONE · 03.10.2024 · 19 (10) · e0311357
DOI: 10.1371/journal.pone.0311357 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 03.10.2024. Verfasst von Miriana d'Alessandro und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical and Surgical Sciences & Neurosciences, Respiratory Diseases Unit, University of Siena, Siena, Italy. Hauptthemen laut MEDLINE: Biomarkers, Lung Diseases, Interstitial, Autoimmune Diseases, Rheumatic Diseases. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Interstitial lung disease (ILD) may complicate the course of systemic autoimmune rheumatic disease (SARD) and diagnostic biomarkers are needed. Krebs von den Lungen-6 (KL-6), ferritin (FER) and interleukin 6 (IL-6) have been involved in the ILD development. Our study aimed to compare KL-6, FER, IL-6 and soluble mesothelin-related peptide (SMRP) concentrations in a cohort of idiopathic and SARD-ILD.
Methods
3169 patients were enrolled in the “UK Biomarkers in Interstitial Lung Disease (UK-BILD) Study”. We selected patients affected by SARD-ILD and idiopathic ILD (usual interstitial pneumonia-idiopathic pulmonary fibrosis and fibrotic non-specific interstitial pneumonia). Serum marker concentrations were measured through chemiluminescent assays (Fujirebio Europe, Ghent, Belgium).
Results
1013 patients were selected for the study: 520 (51.3%) had idiopathic ILD and 493 (48.7%) SARD-ILD. Idiopathic ILD patients displayed higher KL-6 values than SARD-ILD (p = 0.0002). FER and SMRP, though within normal ranges, were significantly higher in idiopathic ILD (p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical and Surgical Sciences & Neurosciences, Respiratory Diseases Unit, University of Siena, Siena, Italy.
- Department of Rheumatology, Liverpool University Hospitals NHS Foundation Trust, Liverpool, United Kingdom.
- Epidemiology and Public Health Group, School of Health Sciences, University of Manchester, Manchester, United Kingdom.
- Aintree Chest Centre, Aintree Hospital, Liverpool, United Kingdom.
- Department of Medicine, Surgery & Neurosciences, Rheumatology Unit, University of Siena, Siena, Italy.
- Faculty of Biology, Medicine and Health, Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester, United Kingdom.
ORCID-Profile: Miriana d'Alessandro, Hector Chinoy
Zitieren
APA
d'Alessandro, M., Cameli, P., Cotton, C. V., Lamb, J. A., Bergantini, L., Gangi, S., Sugden, S., Spencer, L. G., Frediani, B., New, R. P., Chinoy, H., Bargagli, E., & Conticini, E. (2024). Panel of serum biomarkers for differential diagnosis of idiopathic interstitial lung disease and interstitial lung disease-secondary to systemic autoimmune rheumatic disease. PLOS ONE, 19(10), e0311357. https://doi.org/10.1371/journal.pone.0311357
Vancouver
d'Alessandro M, Cameli P, Cotton CV, Lamb JA, Bergantini L, Gangi S, et al. Panel of serum biomarkers for differential diagnosis of idiopathic interstitial lung disease and interstitial lung disease-secondary to systemic autoimmune rheumatic disease. PLOS ONE. 2024;19(10):e0311357. doi:10.1371/journal.pone.0311357
BibTeX
@article{dAlessandro2024,
author = {d'Alessandro, Miriana and Cameli, Paolo and Cotton, Caroline V and Lamb, Janine A and Bergantini, Laura and Gangi, Sara and Sugden, Sarah and Spencer, Lisa G and Frediani, Bruno and New, Robert P and Chinoy, Hector and Bargagli, Elena and Conticini, Edoardo},
title = {Panel of serum biomarkers for differential diagnosis of idiopathic interstitial lung disease and interstitial lung disease-secondary to systemic autoimmune rheumatic disease},
journal = {PLOS ONE},
year = {2024},
volume = {19},
number = {10},
pages = {e0311357},
doi = {10.1371/journal.pone.0311357}
}
EUVIMED